Purchase by Samsara Opportunity Fund, L.P.
244,300 shares · @ $4.83 · $1,179,969
Kalaris Therapeutics, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $5.27
+5.9% in 1d after detection
Post-detection moves
1h
—
1d
+5.9%
3d
+5.3%
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS